MedTrace Logo

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

NCT00659659 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2012-10-10

No results posted yet for this study

Summary

Evaluate the safety and tolerability of MEDI-563 in adults with asthma and the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies

Conditions

Interventions

DRUG

MEDI-563

1.0 mg/kg IV: MEDI-563

DRUG

MEDI-563

100 mg, 200 mg SC

OTHER

Placebo Comp.

Placebo SC

OTHER

Placebo

Placebo as a single IV infusion (Certain number of subjects)

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • David Gossage, M.D., MBA · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-01-31
Completion
2011-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659659 on ClinicalTrials.gov